• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion.静脉输注后健康志愿者中前列地尔(前列腺素E1)的剂量比例药代动力学。
Br J Clin Pharmacol. 1995 Sep;40(3):273-6. doi: 10.1111/j.1365-2125.1995.tb05784.x.
2
Metabolism and pharmacokinetics of prostaglandin E1 administered by intravenous infusion in human subjects.静脉输注前列腺素E1在人体中的代谢及药代动力学。
Eur J Clin Pharmacol. 1994;46(3):275-7. doi: 10.1007/BF00192562.
3
Determination of prostaglandin E1 and its main plasma metabolites 15-keto-prostaglandin E0 and prostaglandin E0 by gas chromatography/negative ion chemical ionization triple-stage quadrupole mass spectrometry.
Biol Mass Spectrom. 1994 Mar;23(3):165-70. doi: 10.1002/bms.1200230308.
4
Gas chromatography/negative ion chemical ionization triple quadrupole mass spectrometric determination and pharmacokinetics of 11 alpha-hydroxy-9,15-dioxo-2,3,4,5,20-pentanor-19-carboxyprostan oic acid in plasma.血浆中11α-羟基-9,15-二氧代-2,3,4,5,20-五降-19-羧基前列腺素的气相色谱/负离子化学电离三重四极杆质谱测定及药代动力学
Prostaglandins Leukot Essent Fatty Acids. 1994 Dec;51(6):401-5. doi: 10.1016/0952-3278(94)90055-8.
5
On the metabolism of prostaglandin E1 administered intravenously to human volunteers.关于静脉注射前列腺素E1给人类志愿者后的代谢情况。
J Physiol Pharmacol. 1991 Sep;42(3):327-31.
6
Simultaneous determination of prostaglandin E1, prostaglandin E0 and 15-keto-prostaglandin E0 in human plasma by gas chromatography/negative-ion chemical-ionization tandem mass spectrometry.气相色谱/负离子化学电离串联质谱法同时测定人血浆中的前列腺素E1、前列腺素E0和15-酮基-前列腺素E0
J Chromatogr A. 1999 Jun 25;847(1-2):187-202. doi: 10.1016/s0021-9673(99)00166-1.
7
Pulmonary extraction and pharmacokinetics of prostaglandin E1 during continuous intravenous infusion in patients with adult respiratory distress syndrome.
Am Rev Respir Dis. 1988 Jan;137(1):5-12. doi: 10.1164/ajrccm/137.1.5.
8
[Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease].[外周动脉闭塞性疾病患者静脉注射前列腺素E1的代谢]
Wien Klin Wochenschr. 1991;103(18):554-7.
9
Formation of biologically active 13,14-dihydro-prostaglandin E1 during intravenous infusion of prostaglandin E1 in newborns with ductus arteriosus-dependent congenital heart disease.在患有动脉导管依赖性先天性心脏病的新生儿静脉输注前列腺素E1期间生物活性13,14-二氢前列腺素E1的形成。
Br J Clin Pharmacol. 1992 Mar;33(3):323-5. doi: 10.1111/j.1365-2125.1992.tb04044.x.
10
Interindividual variation in the enzymatic 15-keto-reduction of 13,14-dihydro-15-keto-prostaglandin E1 in human liver and in human erythrocytes.
Eur J Clin Pharmacol. 1997;52(2):147-53. doi: 10.1007/s002280050264.

引用本文的文献

1
Expression of the oxygen-sensitive transcription factor subunit HIF-1α in patients suffering from secondary Raynaud syndrome.缺氧诱导因子-1α亚基在继发雷诺综合征患者中的表达。
Acta Pharmacol Sin. 2019 Apr;40(4):500-506. doi: 10.1038/s41401-018-0055-1. Epub 2018 Jul 10.
2
Ischemic preconditioning vs adenosine vs prostaglandin E1 for protection against liver ischemia/reperfusion injury.缺血预处理与腺苷及前列腺素E1对肝脏缺血/再灌注损伤的保护作用比较
Braz J Med Biol Res. 2017 Jul 20;50(8):e6185. doi: 10.1590/1414-431X20176185.
3
Differential roles of prostaglandin E-type receptors in activation of hypoxia-inducible factor 1 by prostaglandin E1 in vascular-derived cells under non-hypoxic conditions.在非缺氧条件下,前列腺素 E1 通过前列腺素 E 型受体激活血管源性细胞中的缺氧诱导因子 1 中,各受体的作用存在差异。
PeerJ. 2013 Nov 28;1:e220. doi: 10.7717/peerj.220. eCollection 2013.
4
Effect of prostaglandin E1 inhalation on pulmonary hypertension following corrective surgery for congenital heart disease.前列腺素E1吸入对先天性心脏病矫正手术后肺动脉高压的影响。
Exp Clin Cardiol. 2013 Winter;18(1):13-6.
5
Antiplatelet agents can promote two-peaked thrombin generation in platelet rich plasma: mechanism and possible applications.抗血小板药物可促进富含血小板血浆中的双峰凝血酶生成:机制与可能的应用。
PLoS One. 2013;8(2):e55688. doi: 10.1371/journal.pone.0055688. Epub 2013 Feb 6.
6
Confidence interval criteria for assessment of dose proportionality.评估剂量比例性的置信区间标准。
Pharm Res. 2000 Oct;17(10):1278-83. doi: 10.1023/a:1026451721686.
7
Prostaglandin E1 infusion and functional hepatic flow in control subjects and in patients with cirrhosis.前列腺素E1输注与健康对照者及肝硬化患者的肝脏功能血流
Dig Dis Sci. 1999 Feb;44(2):377-84. doi: 10.1023/a:1026670921331.

本文引用的文献

1
Determination of prostaglandin E1 and its main plasma metabolites 15-keto-prostaglandin E0 and prostaglandin E0 by gas chromatography/negative ion chemical ionization triple-stage quadrupole mass spectrometry.
Biol Mass Spectrom. 1994 Mar;23(3):165-70. doi: 10.1002/bms.1200230308.
2
Metabolism and pharmacokinetics of prostaglandin E1 administered by intravenous infusion in human subjects.静脉输注前列腺素E1在人体中的代谢及药代动力学。
Eur J Clin Pharmacol. 1994;46(3):275-7. doi: 10.1007/BF00192562.
3
Simulation of pharmacokinetic behaviour of drug-cyclodextrin complexes.药物-环糊精复合物药代动力学行为的模拟
Pharmazie. 1984 Dec;39(12):830-4.
4
On the metabolism of prostaglandins E 1 and E 2 in man.关于前列腺素E1和E2在人体中的代谢
J Biol Chem. 1971 Nov 25;246(22):6713-21.
5
Relationship between chemical structure and platelet-aggregation activity of prostaglandins.前列腺素的化学结构与血小板聚集活性之间的关系。
Biochim Biophys Acta. 1969 Oct 28;187(3):285-92. doi: 10.1016/0005-2760(69)90001-0.
6
Endogenous levels of 15-keto-dihydro-prostaglandins in human plasma. Parameters for monitoring prostaglandin synthesis.人血浆中15-酮-二氢前列腺素的内源性水平。监测前列腺素合成的参数。
Biochem Med. 1974 Nov;11(3):298-303. doi: 10.1016/0006-2944(74)90127-6.
7
Haemodynamic effects of intra-arterial and intravenous administration of prostaglandin E1 in patients with peripheral arterial disease.外周动脉疾病患者动脉内和静脉内注射前列腺素E1的血流动力学效应。
Br J Surg. 1986 Jan;73(1):20-3. doi: 10.1002/bjs.1800730109.
8
Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease--a controlled randomised multicenter study.静脉注射前列腺素E1与己酮可可碱治疗慢性动脉闭塞性疾病——一项对照随机多中心研究
Vasa Suppl. 1989;28:44-9.
9
On the metabolism of prostaglandin E1 administered intravenously to human volunteers.关于静脉注射前列腺素E1给人类志愿者后的代谢情况。
J Physiol Pharmacol. 1991 Sep;42(3):327-31.
10
Clinical, hemodynamic and metabolic effects of intraarterial infusions of prostaglandin E1 in patients with peripheral vascular disease.前列腺素E1动脉内输注对周围血管疾病患者的临床、血流动力学及代谢影响
Adv Prostaglandin Thromboxane Res. 1976;1:429-32.

静脉输注后健康志愿者中前列地尔(前列腺素E1)的剂量比例药代动力学。

Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion.

作者信息

Cawello W, Leonhardt A, Schweer H, Seyberth H W, Bonn R, Lomeli A L

机构信息

Preclinical Research, Schwarz Pharma AG, Monheim am Rhein, Germany.

出版信息

Br J Clin Pharmacol. 1995 Sep;40(3):273-6. doi: 10.1111/j.1365-2125.1995.tb05784.x.

DOI:10.1111/j.1365-2125.1995.tb05784.x
PMID:8527291
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1365109/
Abstract

Prostaglandin E1 (PGE1) (30, 60, 120 micrograms) was administered by intravenous infusion over a 120 min period in an open, three way randomized, cross-over study to 12 healthy male volunteers. For the evaluation of PGE1, PGE0 and 15-keto-PGE0, blood samples were drawn prior to, during and after the infusion. Analytical measurements were performed by gas chromatography/negative ion chemical ionization triple stage quadruple mass spectrometry, a highly specific and sensitive GC/MS/MS-method. During intravenous infusion of 30, 60 and 120 micrograms PGE1, endogenous plasma PGE1 concentrations increased from 1.7 +/- 0.8 to 4.2 +/- 1.1, 6.7 +/- 1.0 and 11.0 +/- 1.9 pg ml-1 respectively. PGE0 plasma concentrations increased from endogenous levels of 1.3 +/- 1.0 pg ml-1 to 7.6 +/- 2.1, 14.1 +/- 3.7 and 28.0 +/- 3.0 pg ml-1 respectively, whilst 15-keto-PGE0 plasma concentrations increased from endogenous levels of 10.2 +/- 13.9 pg ml-1 to 99.3 +/- 27.9, 190.4 +/- 52.5 and 357.2 +/- 72.6 pg ml-1 respectively. Within the dose range of 30-120 micrograms PGE1 2 h-1 there was a linear increase of Cmax and AUC with the dose. The results of the analysis of variance after baseline and dose-correction show a 90% confidence interval in the bioequivalence acceptance range of 80 to 125%.

摘要

在一项开放性、三向随机交叉研究中,对12名健康男性志愿者在120分钟内静脉输注前列腺素E1(PGE1)(30、60、120微克)。为了评估PGE1、PGE0和15-酮-PGE0,在输注前、输注期间和输注后采集血样。分析测量通过气相色谱/负离子化学电离三级四极杆质谱法进行,这是一种高度特异性和灵敏的气相色谱/串联质谱法。在静脉输注30、60和120微克PGE1期间,内源性血浆PGE1浓度分别从1.7±0.8增加到4.2±1.1、6.7±1.0和11.0±1.9皮克/毫升。PGE0血浆浓度分别从内源性水平1.3±1.0皮克/毫升增加到7.6±2.1、14.1±3.7和28.0±3.0皮克/毫升,而15-酮-PGE0血浆浓度分别从内源性水平10.2±13.9皮克/毫升增加到99.3±27.9、190.4±52.5和357.2±72.6皮克/毫升。在PGE1 2小时-1剂量范围为30 - 120微克时,Cmax和AUC随剂量呈线性增加。基线和剂量校正后的方差分析结果显示,生物等效性接受范围在80%至125%的90%置信区间内。